Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease

Abstract

AbstractObjectivesPleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic intrathoracic extracorporeal chemotherapy (HITEC) in patients who underwent pleurectomy/decortication (P/D) for secondary malignant pleural disease (SPD).MethodsA total of 101 patients were evaluated over 72 months, with 35 patients electing to proceed with P/D and 60 minutes of HITEC with cisplatin at 42°C. Inclusion criteria were adults 18–79 years with unilateral pleural dissemination. Exclusion criteria were patients without control of primary site, extrathoracic metastatic disease, significant comorbidities, and a history of adverse reaction to cisplatin.ResultsMedian age was 56 years (36–73); 60% were women. SPD was thymoma in 13, breast cancer in 9, lung cancer in 6, colon cancer in 2, renal cell in 2, and esophageal, anal, and thymic cancers in one each. There was no operative mortality. Postoperative complications occurred in 18 patients (51%). No patient developed renal failure. Median follow‐up was 24 months (4–60). The overall survival rate was 61%; 17 patients (49%) developed recurrent disease at a median of 12 months (6–36). There were no recurrences after 36 months Eleven patients (31%) died of metastatic disease at a median of 17 months (7–25).ConclusionsSurgical cytoreduction of SPD followed by HITEC with cisplatin was well tolerated. No patient developed cisplatin‐related toxicities. Long‐term follow‐up is warranted to determine survival advantage and refinement of inclusion criteria.